Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from... von André, T., Lonardi, S., Wong, K.Y.M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M.A., Van Cutsem, E., McDermott, R., Hill, A., Sawyer, M.B., Hendlisz, A., Neyns, B., Abdullaev, S., Memaj, A., Lei, M., Dixon, M., Kopetz, S., Overman, M.J.

Volltext

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update von Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.

Volltext

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis von Borghaei, H., Ciuleanu, T.-E., Lee, J.-S., Pluzanski, A., Caro, R. Bernabe, Gutierrez, M., Ohe, Y., Nishio, M., Goldman, J., Ready, N., Spigel, D.R., Ramalingam, S.S., Paz-Ares, L.G., Gainor, J.F., Ahmed, S., Reck, M., Maio, M., O’Byrne, K.J., Memaj, A., Nathan, F., Tran, P., Hellmann, M.D., Brahmer, J.R.

Volltext

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year... von Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.

Volltext

P376 Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis von Sands, B E, Jain, A, Ahmad, H A, Osterman, M, Memaj, A, Canavan, J B, Axelrad, J E

Volltext

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from... von Andre, T, Lonardi, S, Wong, K.Y.M, Lenz, H.-J, Gelsomino, F, Aglietta, M, Van Cutsem, E, McDermott, R, Hill, A, Sawyer, M.B, Hendlisz, A, Neyns, B, Abdullaev, S, Memaj, A, Lei, M, Dixon, M, Kopetz, S, Overman, M.J, Morse, M.A

Volltext

DOP43 Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True N... von Siegmund, B, Axelrad, J, Pondel, M, Osterman, M T, Ahmad, H A, Memaj, A, Regueiro, M, Armuzzi, A, Afzali, A

Volltext

SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-u... von André, T., Lonardi, S., Wong, K., Lenz, H., Gelsomino, F., Aglietta, M., Morse, M., Van Cutsem, E., McDermott, R., Hill, A., Sawyer, M., Hendlisz, A., Neyns, B., Abdullaev, S., Memaj, A., Lei, M., Kopetz, S., Overman, M.

Volltext

P585 Duration of response to ozanimod after treatment withdrawal: results from the phase 3 True North study von Vermeire, S, Abraham, B, Bressler, B, Reinisch, W, Jain, A, Memaj, A, Akukwe, L, Liu, W J, Osterman, M, Canavan, J B, Sands, B E

Volltext

P752 Predictors of time to relapse upon ozanimod withdrawal in patients with moderately to severely active ulcerative colitis von Vermeire, S, Abraham, B, Bressler, B, Reinisch, W, Axelrad, J E, Jain, A, Memaj, A, Akukwe, L, Liu, W J, Osterman, M T, Canavan, J B, Sands, B E

Volltext

First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update (vol 6,... von Reck, M., Ciuleanu, T. -E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P. -J., De Marchiy, P., Martin, C., Perol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D. P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.

Volltext

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year... von Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.

Volltext

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial von Paz-Ares, Luis G., Ramalingam, Suresh S., Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Urban, Laszlo, Caro, Reyes Bernabe, Park, Keunchil, Sakai, Hiroshi, Ohe, Yuichiro, Nishio, Makoto, Audigier-Valette, Clarisse, Burgers, Jacobus A., Pluzanski, Adam, Sangha, Randeep, Gallardo, Carlos, Takeda, Masayuki, Linardou, Helena, Lupinacci, Lorena, Lee, Ki Hyeong, Caserta, Claudia, Provencio, Mariano, Carcereny, Enric, Otterson, Gregory A., Schenker, Michael, Zurawski, Bogdan, Alexandru, Aurelia, Vergnenegre, Alain, Raimbourg, Judith, Feeney, Kynan, Kim, Sang-We, Borghaei, Hossein, O'Byrne, Kenneth John, Hellmann, Matthew D., Memaj, Arteid, Nathan, Faith Ellen, Bushong, Judith, Tran, Phuong, Brahmer, Julie R., Reck, Martin

Volltext

Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology von Memaj, Plator, Jornayvaz, François R

Volltext

Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease von Memaj, Plator, Ouzerara, Zayd, Jornayvaz, François R

Volltext

International Cartels Logic and Cases von Bejleri, Emirjeta, Memaj, Gentian

Volltext

The Life Insurance Market in Albania and the Factors that Affect its Development von Biçoku, Jonida, Memaj, Fatmir

Volltext

Porter Framework vs A More Extended Framework von BEJLERI, Emirjeta, KRAJA, Ylvije Boriçi, MEMAJ, Gentian

Volltext

Non-Alcoholic Fatty Liver Disease and Diabetes: the bad marriage von Nascè, Alberto, Memaj, Plator, Jornayvaz, François R

Volltext

Recycling Behavior Case of Shkodra, Albania von Bejleri, Emirjeta, Memaj, Gentian, Dragusha, Blerta

Volltext